An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Status:
RECRUITING
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
Phase:
PHASE2
Details
Lead Sponsor:
ToLymph Inc.
Collaborators:
Mayo Clinic Ozmosis Research Inc. University Health Network (UHN)